Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 151 of 5804
-
New trial aims to boost survival in rare blood disease with stem cell transplant
Disease control Recruiting nowThis phase III trial compares the effect of adding a stem cell transplant with melphalan after completing chemotherapy with daratumumab, cyclophosphamide, bortezomib and dexamethasone (Dara-VCD) versus chemotherapy with Dara-VCD alone for treating patients with newly diagnosed am…
Phase: PHASE3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Could a Naltrexone-Bupropion combo curb meth addiction? new trial seeks answers
Disease control OngoingThe primary objective of this study is to evaluate the efficacy of extended release naltrexone plus bupropion XL (XR-NTX/BUP-XL) compared to matched injectable and oral placebo (iPLB/oPLB) in reducing methamphetamine (MA) use in individuals with moderate or severe methamphetamine…
Phase: PHASE3 • Sponsor: National Institute on Drug Abuse (NIDA) • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New hope for head and neck cancer: experimental drug petosemtamab enters final testing
Disease control Recruiting nowThis is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent disease.
Phase: PHASE3 • Sponsor: Merus B.V. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
CRISPR therapy takes aim at stubborn high cholesterol in first human trial
Disease control Recruiting nowThis is a single-arm, open-label, multicenter, ascending dose Phase 1 trial that will enroll participants 18 to 75 years of age with dyslipidemias that are refractory to available treatments.
Phase: PHASE1 • Sponsor: CRISPR Therapeutics AG • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Gene-Editing shot aims to fix lung and liver damage in rare disease
Disease control Recruiting nowThis is a Phase 1/2, multicenter, open-label, dose-exploration (Phase 1) and dose-expansion (Phase 2) study to evaluate the safety, tolerability, PK/PD, and efficacy of BEAM-302 in adult patients with AATD-associated lung disease and/or liver disease and to determine the optimal …
Phase: PHASE1, PHASE2 • Sponsor: Beam Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Can a new drug calm the storm of bipolar mania?
Symptom relief CompletedThis is a multicenter, randomized, double-blind, placebo-controlled, study in the acute treatment of patients with a diagnosis of bipolar I disorder with manic episodes or manic episodes with mixed features (bipolar mania), with or without psychotic symptoms, according to criteri…
Phase: PHASE3 • Sponsor: Intra-Cellular Therapies, Inc. • Aim: Symptom relief
Last updated Jul 26, 2026 00:00 UTC
-
New antibody combo aims to stall multiple Myeloma's return
Disease control Recruiting nowThe purpose of this study is to evaluate the effects of the addition of SG301 injection to pomalidomide and dexamethasone in subjects with relapsed or refractory multiple myeloma.
Phase: PHASE3 • Sponsor: Hangzhou Sumgen Biotech Co., Ltd. • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Can a Two-Drug attack shrink tough lung cancers?
Disease control Recruiting nowThis study is a phase II clinical study to explore the efficacy and safety of BL-B01D1 + PD-1 monoclonal antibody combination therapy in patients with extensive-stage small cell lung cancer.
Phase: PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Radioactive injection targets Hard-to-Treat tumors in new trial
Disease control Recruiting nowThis is a multicenter, single-arm, two-part study designed to evaluate the safety and efficacy of Lutetium \[177Lu\] Oxyoctreotide Injection in patients with inoperable, locally advanced or metastatic, progressive, advanced somatostatin receptor (SSTR) positive neuroendocrine neo…
Phase: PHASE2, PHASE3 • Sponsor: Sinotau Pharmaceutical Group • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Gene therapy trial hopes to ease Parkinson's symptoms
Disease control Recruiting nowThe objective of this randomized, surgically controlled, double-blinded, Phase 2 study is to evaluate the safety and efficacy of AAV2-GDNF delivered to the putamen in subjects with moderate Parkinson's Disease.
Phase: PHASE2 • Sponsor: AskBio Inc • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Can a Two-Drug attack shrink Hard-to-Treat head and neck tumors?
Disease control Recruiting nowThis study is a phase II clinical study to explore the efficacy and safety of BL-B01D1 + PD-1 monoclonal antibody combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma (non-nasopharyngeal carcinoma) and other solid tumors.
Phase: PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New targeted therapy aims at Hard-to-Treat bile duct cancers
Disease control OngoingThis study was to evaluate the efficacy and safety of SHR-A1811 in patients with locally advanced unresectable or recurrent metastatic BTC with HER2 expression / amplification who failed first-line or second-line systemic treatment.
Phase: PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Organoid-Guided drug trial offers hope for cystic fibrosis patients with rare mutations
Disease control CompletedCF is caused by mutations in the gene that encodes the 'Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)' channel. To re-establish the function of this complex chloride channel, typically two to three drug modes of action are needed. To date, clinical studies of CFTR mo…
Phase: PHASE2 • Sponsor: Kors van der Ent • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Hope for muscle strength: new drug targets myotonic dystrophy
Disease control OngoingA Phase 3 Randomized, Double-Blind, Placebo-Controlled, Global Study to Evaluate the Efficacy and Safety of Intravenous Delpacibart Etedesiran (abbreviated del-desiran, formerly AOC 1001) for the Treatment of Myotonic Dystrophy Type 1
Phase: PHASE3 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New drug duo aims to control lymphoma without chemo
Disease control Recruiting nowTo learn if the chemotherapy-free combination of pirtobrutinib (also called LOXO-305) and rituximab can help provide long term remission in low and intermediate risk MCL.
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could a drug replace surgery for some colon cancers?
Disease control OngoingTo learn if cemiplimab can help to control dMMR colon cancer.
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New shot could ease painful skin condition
Disease control CompletedThis is a study to evaluate the clinical efficacy and safety of sonelokimab administered subcutaneously compared with placebo in the treatment of adult participants with moderate to severe hidradenitis suppurativa. Participants will be randomized 2:1 to either sonelokimab or matc…
Phase: PHASE3 • Sponsor: MoonLake Immunotherapeutics AG • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for Hard-to-Treat lymphoma: golidocitinib faces final test
Disease control Recruiting nowThis is a phase 3, open-label, randomized, multinational study to evaluate the anti-tumor efficacy of golidocitinib versus investigator's choice in adult patients with relapsed/refractory peripheral T-cell lymphoma (r/r PTCL). This study will treat patients with pathologically co…
Phase: PHASE3 • Sponsor: Dizal Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New stroke trial combines clot removal with stenting to save brain function
Disease control Recruiting nowThe primary objective is to establish the efficacy of intra-arterial (IA) mechanical thrombectomy (MT) with extracranial proximal carotid artery acute stenting versus non-stenting approaches in patients with acute ischemic stroke (AIS) from intracranial vessel occlusion (IVO) in …
Phase: PHASE3 • Sponsor: Mercy Health Ohio • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New combo attack on tough lymphoma: two immune therapies join forces
Disease control Recruiting nowTo learn if the combination of axicabtagene ciloleucel (axi-cel) and glofitamab as first-line therapy in high-risk LBCL participants or as second-line therapy in LBCL participants can help to control the disease.
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC